Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Duke Energy Corp (DUK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Duke Energy Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Duke Energy Corp trades at $126.01 (market cap $97.82B). The key difference: Duke Energy Corp is far larger — about 2.5× Alnylam Pharmaceuticals, Inc.'s market cap, and Duke Energy Corp pays a 3.39% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | DUK | |
|---|---|---|
Market Cap | $39.89B | $97.82B |
Sector | Health | Utilities |
52-Week High | $491.22 | $133.46 |
52-Week Low | $278.09 | $113.99 |
Enterprise Value | $38.15B | $187.87B |
Dividend Yield | — | 3.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Duke Energy (DUK) trades at $125.48, up 0.18% on the day, with a bearish technical signal despite recent earnings beats. The stock shows stable revenue growth to $32.24B in 2025 and a net income margin of 15.49%, supported by a dividend yield from its recent $1.07 payout. Analyst consensus is mixed with 40.6% buy ratings and a $137.67 price target, indicating potential upside. Technical resistance sits at $127, with support at $124.
DUK offers defensive appeal with consistent profitability and dividend reliability, but faces headwinds from high debt levels (46.17% debt-to-asset ratio) and capital-intensive infrastructure demands. The stock's neutral RSI and bearish moving averages suggest near-term consolidation, while long-term growth hinges on execution in a regulated utility environment amid rising data center energy demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →
